EMPA-REG OUTCOME: Consistent reduction in risk of cardiovascular outcomes and mortality with empagliflozin irrespective of sulphonylurea use at baseline

被引：0
|
作者：
Inzucchi, S. E. [1 ]
George, J. T. [2 ]
Fitchett, D. [3 ]
Mattheus, M. [2 ]
Janista, C. [2 ]
Zinman, B. [4 ]
机构：
[1] Yale Univ, Sch Med, Sect Endocrinol, New Haven, CT USA
[2] Boehringer Ingelheim Pharma GmbH & Co KG, Therapeut Area Metab, Ingelheim, Germany
[3] Univ Toronto, St Michaels Hosp, Div Cardiol, Toronto, ON, Canada
[4] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON, Canada
来源：
DIABETIC MEDICINE | 2018年 / 35卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P190
引用
收藏
页码：96 / 96
页数：1
相关论文
共 50 条
  • [41] CARDIOVASCULAR OUTCOMES ACCORDING TO LDL CHOLESTEROL LEVELS IN EMPA-REG OUTCOME
    Lee, Dae Wook
    Langslet, Gisle
    Zinman, Bernard
    Wanner, Christoph
    Hantel, Stefan
    Espadero, Rosa-Maria
    Johansen, Odd Erik
    Fitchett, David
    JOURNAL OF HYPERTENSION, 2016, 34 : E518 - E518
  • [42] Empagliflozin improves renal outcomes in patients with or without heart failure at baseline - insights from the EMPA-REG OUTCOME trial
    Butler, J. Javed
    Zannad, F.
    Fitchett, D.
    Zinman, B.
    Koitka-Weber, A.
    Von Eynatten, M.
    Hehnke, U.
    George, J.
    Brueckmann, M.
    Cheung, A. K.
    Wanner, C.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 380 - 381
  • [43] Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME®
    Kaku, Kohei
    Lee, Jisoo
    Mattheus, Michaela
    Kaspers, Stefan
    George, Jyothis
    Woerle, Hans-Juergen
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    Lamkanfi, F.
    CIRCULATION JOURNAL, 2017, 81 (02) : 227 - +
  • [44] EFFECTS OF EMPAGLIFLOZIN ON RENAL OUTCOMES ACROSS KDIGO RISK CATEGORIES: RESULTS FROM THE EMPA-REG OUTCOME® TRIAL
    Wanner, Christoph
    Levin, Adeera
    Perkovic, Vlado
    Koitka-Weber, Audrey
    Mattheus, Michaela
    von Eynatten, Maximilian
    Wheeler, David
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
  • [45] Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial
    Verma, Subodh
    Leiter, Lawrence A.
    Zinman, Bernard
    Sharma, Abhinav
    Mattheus, Michaela
    Fitchett, David
    George, Jyothis
    Ofstad, Anne Pernille
    Kosiborod, Mikhail N.
    Wanner, Christoph
    Inzucchi, Silvio E.
    ESC HEART FAILURE, 2021, 8 (04): : 2603 - 2607
  • [46] Reduction in Cardiovascular (CV) Death with Empagliflozin Is Consistent across Categories of Baseline HbA1c and Change in HbA1c: Results from EMPA-REG OUTCOME
    Inzucchi, Silvio E.
    Fitchett, David
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis T.
    Woerle, Hans J.
    Zinman, Bernard
    DIABETES, 2017, 66 : A313 - A313
  • [47] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. J.
    Inzucchi, S. E.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1191 - 1192
  • [48] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
    Verma, Subodh
    Mazer, C. David
    Bhatt, Deepak L.
    Raj, Satish R.
    Yan, Andrew T.
    Verma, Atul
    Ferrannini, Ele
    Simons, Gudrun
    Lee, Jisoo
    Zinman, Bernard
    George, Jyothis T.
    Fitchett, David
    DIABETES CARE, 2019, 42 (03) : E42 - E44
  • [49] Effect of Empagliflozin on Heart Failure Outcomes in Subgroups by Age: Results from EMPA-REG Outcome
    Monteiro, Pedro
    Schaper, Nicolaas
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    DIABETES, 2016, 65 : A291 - A291
  • [50] EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME
    Lee, Dae Wook
    Monteiro, Pedro
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    JOURNAL OF HYPERTENSION, 2016, 34 : E520 - E520
12345